Analysis Tools
homeostasis/metabolism
|
• at 4-6 weeks after tamoxifen treatment, ex vivo perfused working hearts show a significant reduction in myocardial triacylglycerol (TAG) content relative to control hearts
|
|
• following ischemia/reperfusion, ex vivo perfused working hearts from tamoxifen-treated mice display significantly improved myocardial functional recovery relative to control hearts, as shown by increased heart rate peak systolic pressure (HR PSP) and cardiac power compared to the pre-ischemic phase
• improved recovery is associated with lower calculated proton production prior to and following ischemia relative to control hearts
• during reperfusion, ATP production relative to cardiac work is dramatically reduced and myocardial lactate levels are significantly decreased, indicating increased post-ischemic cardiac efficiency relative to control hearts
|
|
• at 4-6 weeks after tamoxifen treatment, ex vivo perfused working hearts show a 48% reduction in FA (palmitate) oxidation rates relative to control hearts
|
|
• at 4-6 weeks after tamoxifen treatment, ex vivo perfused working hearts show a 68% increase in glucose oxidation rates, with no significant change in glycolytic rates relative to control hearts
• despite switch to increased mitochondrial oxidation of glucose versus FAs (53% of TCA cycle acetyl-CoA production versus 26% in controls), total TCA cycle acetyl-CoA production and total ATP production via exogenously supplied substrates are not significantly altered
|
|
• at 4-6 weeks after tamoxifen treatment, ex vivo perfused working hearts display significantly decreased fatty acid (palmitate) uptake relative to control hearts
• however, serum concentrations of free FAs are not significantly altered
|
muscle
|
• at 4-6 weeks after tamoxifen treatment, ex vivo perfused working hearts show a significant reduction in myocardial triacylglycerol (TAG) content relative to control hearts
|
cardiovascular system
| N |
• at 4-6 weeks after tamoxifen treatment, H&E staining showed normal cardiomyocyte morphology in apical heart sections
• ex vivo perfused working hearts show normal heart rate (HR), HR peak systolic pressure (PSP), cardiac power, cardiac output and coronary flow rates, as well as normal myocardial ATP, ADP, AMP, and phosphocreatine levels during aerobic perfusions
• in vivo, tamoxifen-treated hearts show normal baseline cardiac function with no detectable structural or morphological abnormalities
|
|
• at 4-6 weeks after tamoxifen treatment, ex vivo perfused working hearts show a significant reduction in myocardial triacylglycerol (TAG) content relative to control hearts
|
|
• following ischemia/reperfusion, ex vivo perfused working hearts from tamoxifen-treated mice display significantly improved myocardial functional recovery relative to control hearts, as shown by increased heart rate peak systolic pressure (HR PSP) and cardiac power compared to the pre-ischemic phase
• improved recovery is associated with lower calculated proton production prior to and following ischemia relative to control hearts
• during reperfusion, ATP production relative to cardiac work is dramatically reduced and myocardial lactate levels are significantly decreased, indicating increased post-ischemic cardiac efficiency relative to control hearts
|
cellular
|
• at 4-6 weeks after tamoxifen treatment, ex vivo perfused working hearts show a 48% reduction in FA (palmitate) oxidation rates relative to control hearts
|
